Euro Could Reach $1.40 Within Two Years: Macro Hive
Macro Hive CEO Bilal Hafeez says the euro could reach $1.40 within one or two years. "There has to be an outlet somewhere for dollar weakness," Hafeez tells Bloomberg Television. FX options show growing appetite for medium-term euro upside. Markets now see nearly a 1-in-2 chance of the single currency trading above $1.20 by the end of 2027, a far cry from a year ago where there was talk of parity. (Source: Bloomberg)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Shares of the company have appreciated by 11.97% over the course of the past month, outperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. At the same time, our most recent consensus estimate is projecting a revenue of $5.89 million, reflecting a 1032.88% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.54 per share and revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.68% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 76, placing it within the top 31% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Vibes Nation
39 minutes ago
- Geek Vibes Nation
How ChatGPT Bots Handle Client DMs While I Sleep – And Land Me New Deals
A good fit Ready to start Needing more info' This prompt works with DM automation tools that support branching logic. I collect info while I sleep – and wake up knowing which leads are warm. Claude Prompt #6 – Turn Chat Transcripts Into CRM Notes Prompt: 'Summarize this DM chat into 3 bullet points for my CRM: Who they are What they need How to follow up' This is huge when you're juggling 20 conversations. Claude acts like a personal assistant that cleans up your notes, flags key info, and saves it to Notion, Airtable, or whatever you use. AI DM Bot Comparison Use Case Best Model Why It Works Warm intro DM ChatGPT Fast, friendly, low-friction copy Deep context follow-up Claude Reads nuance and builds trust FAQ automation ChatGPT Clear, reusable, scalable replies Lead qualification Claude Detects readiness, helps filter CRM note generation Claude Great for summarizing long convos The Real Win – Focus on Closing, Not Replying Since I implemented this ChatGPT + Claude + Chatronix setup, I spend less time chasing leads and more time closing deals. I don't lose prospects because I replied too late. I don't drop the ball on follow-ups. And I don't miss qualified leads buried in my DMs. It's not about automating relationships – it's about automating friction so real connection can happen. Want your DMs to work while you rest? ✅ Visit Chatronix and set up your dream AI sales assistant – without hiring anyone. Emily Henry writes for UKWritings Reviews and Write My Research Paper . She writes articles on many subjects including writing great resumes. Emily is also an editor at State Of Writing .
Axios
2 hours ago
- Axios
U.S., China reach "framework" to activate Geneva trade deal
The U.S. and China have agreed on a "framework" to implement a trade deal struck last month, pending approval from both countries' leaders, Commerce Secretary Howard Lutnick said on Tuesday. Why it matters: Progress on trade peace with China, particularly if it resolves the issue of crucial Chinese rare earth minerals exports, would be a boon to an economy and markets that have struggled for months with the impact of President Trump's tariff program. Catch up quick: After a series of tit-for-tat retaliations in April, the world's two largest economies effectively had a trade embargo in place, with 145% U.S. tariffs crushing imports from China. The sides announced a trade deal that included a 90-day pause on most of those tariffs on May 12 after a weekend of high-level talks in Geneva. Only days later, the U.S. issued global restrictions on the use of certain Chinese chips from Huawei Ascend, saying they were developed in violation of U.S. export controls. The Chinese reacted furiously, and soon there were reports the government was restricting exports of the rare earth materials needed for hundreds of the world's most important high-tech products. The U.S. subsequently retaliated with a move to restrict and withdraw visas for Chinese students. Where it stands: Trump and Chinese leader Xi Jinping spoke for 90 minutes last Thursday about trade issues, and agreed to high-level talks immediately. That led to this week's meeting in London. "We have reached a framework to implement the Geneva consensus," Lutnick told reporters in London Tuesday night after marathon trade talks, Bloomberg reported. The Wall Street Journal reported that Tuesday's deal would essentially get the May 12 deal back on track, including the lowered tariffs and the loosened Chinese restrictions on rare earths. Between the lines: The trade war is squeezing both economies.
